
Electra Therapeutics, Inc. (NASDAQ:ETRA – Free Report) – Investment analysts at HC Wainwright dropped their FY2026 earnings per share estimates for Electra Therapeutics in a research report issued to clients and investors on Monday, November 16th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($5.64) per share for the year, down from their prior forecast of ($3.17). HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Electra Therapeutics’ current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Electra Therapeutics’ Q4 2026 earnings at ($0.48) EPS, Q1 2027 earnings at ($0.52) EPS, Q2 2027 earnings at ($0.58) EPS, Q3 2027 earnings at ($0.62) EPS, Q4 2027 earnings at ($0.68) EPS and FY2027 earnings at ($2.41) EPS.
Several other analysts have also weighed in on ETRA. Jefferies Financial Group assumed coverage on Electra Therapeutics in a report on Tuesday, October 13th. They set a “buy” rating and a $32.00 price target on the stock. Evercore assumed coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They set an “outperform” rating and a $36.00 price objective for the company. JPMorgan Chase & Co. began coverage on shares of Electra Therapeutics in a research report on Thursday, October 22nd. They set an “overweight” rating and a $36.00 price objective on the stock. Zacks Research upgraded shares of Electra Therapeutics to a “hold” rating in a research report on Wednesday, October 14th. Finally, Wall Street Zen raised shares of Electra Therapeutics to a “hold” rating in a research note on Saturday, September 26th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Electra Therapeutics currently has an average rating of “Buy” and a consensus target price of $33.50.
Read Our Latest Research Report on Electra Therapeutics
Electra Therapeutics Stock Performance
NASDAQ ETRA opened at $8.35 on Wednesday. The firm’s 50 day moving average is $9.51. Electra Therapeutics has a fifty-two week low of $6.86 and a fifty-two week high of $15.50.
Electra Therapeutics (NASDAQ:ETRA – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($3.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.76) by ($1.71).
Insider Activity at Electra Therapeutics
In other Electra Therapeutics news, Director Orbimed Advisors Llc bought 1,333,333 shares of the business’s stock in a transaction dated Monday, September 21st. The shares were purchased at an average price of $15.00 per share, with a total value of $19,999,995.00. Following the completion of the purchase, the director owned 5,126,891 shares in the company, valued at $76,903,365. This represents a 35.15% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Carl Gordon bought 1,333,333 shares of the business’s stock in a transaction dated Monday, September 21st. The shares were acquired at an average cost of $15.00 per share, for a total transaction of $19,999,995.00. Following the purchase, the director owned 5,126,891 shares of the company’s stock, valued at approximately $76,903,365. The trade was a 35.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 3,796,040 shares of company stock valued at $48,699,065 in the last 90 days.
Hedge Funds Weigh In On Electra Therapeutics
A number of large investors have recently bought and sold shares of ETRA. Goldman Sachs Group Inc. purchased a new stake in Electra Therapeutics in the third quarter worth $1,465,000. Integral Health Asset Management LLC bought a new stake in shares of Electra Therapeutics during the third quarter worth $2,250,000. Soleus Capital Management L.P. bought a new stake in shares of Electra Therapeutics during the third quarter worth $2,812,000. Finally, RA Capital Management L.P. bought a new stake in shares of Electra Therapeutics during the third quarter worth $19,046,000.
About Electra Therapeutics
Electra Therapeutics, Inc. (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra’s lead investigational product is ELA026, an antibody targeting SIRP?, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.
Featured Stories
- Five stocks we like better than Electra Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Electra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
